Glenmark gets USFDA nod for generic Westcort cream used for skin conditions

Glenmark's current portfolio consists of 139 products authorised for distribution in the US marketplace and 60 abbreviated new drug applications (ANDA's) pending approval with the USFDA

Sun Pharma Q4
The revenue from operations declined to ~69.7 bn for the fourth quarter against ~71.3 bn during the same period last year
Press Trust of India New Delhi
Last Updated : Oct 15 2018 | 3:46 PM IST

Don't want to miss the best from Business Standard?

Drug firm Glenmark Pharmaceuticals Monday said it has received final nod from the US health regulator for generic Hydrocortisone Valerate cream used for providing relief in inflammation and itching due to various skin conditions.

Glenmark Pharmaceuticals Inc has been granted final approval by the United States Food & Drug Administration (USFDA) for Hydrocortisone Valerate Cream USP, 0.2 per cent, Glenmark said in a statement.

The product is a generic version of Sun Pharmaceutical Industries Inc's Westcort Cream in the same strength, it added.

According to IQVIA sales data for the 12-month period ending August 2018, the Westcort Cream, 0.2 per cent market achieved annual sales of around $17 million, Glenmark said.
 

The company's current portfolio consists of 139 products authorised for distribution in the US marketplace and 60 abbreviated new drug applications (ANDA's) pending approval with the USFDA, Glenmark said.

Shares of Glenmark Pharmaceuticals were today trading at Rs 611.55 per scrip on BSE, up 1.78 per cent from its previous close in late afternoon trade.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Oct 15 2018 | 3:25 PM IST

Next Story